Japan approved BridgeBio’s acoramidis (Beyonttra) for ATTR-CM, with AstraZeneca’s Alexion handling commercialization. BridgeBio will receive a $30 million milestone payment and low double ...

Known for his bold and often controversial actions, he has dedicated his life to protecting marine wildlife, with Japanese whaling being one of his primary targets. Now, Watson faces a new legal ...

Veteran environmentalist Paul Watson was arrested in Greenland on Sunday and faces possible extradition to Japan allegedly over anti-whaling activities in the Antarctic years ago, his organization ...

Beyfortus (nirsevimab), a single-dose monoclonal antibody developed and commercialized in partnership by AstraZeneca (NASDAQ:AZN) and Sanofi (NASDAQ:SNY), has been approved in Japan for the ...

BridgeBio Pharma is behind the push to bring acoramidis to market in the U.S., but AstraZeneca holds the Japanese rights. Now, AstraZeneca has shared an update on the open-label phase 3 trial ...

(RTTNews) - AstraZeneca reported that Soliris has been approved in Japan for expanded use to include the treatment of generalised myasthenia gravis in paediatric patients who are anti ...

When Japanese pharmaceutical company Daiichi Sankyo Co. discovered a groundbreaking cancer treatment, it turned to bigger Western drugmaker AstraZeneca Plc. to help commercialize the therapy that ...

AstraZeneca's (NASDAQ:AZN) Ultomiris received expanded approval in Japan to prevent relapses in patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder ...

(Mainichi/Kimi Takeuchi) TOKYO -- Japan has discarded some 13.5 million doses of AstraZeneca COVID-19 vaccine as all of the remaining shots supplied by the British pharmaceutical company have ...

(File) GlobalData on Monday said that Japan’s decision to limit AstraZeneca’s Evusheld supply to only COVID-19 prevention will still likely encourage its uptake. Recently, Japan’s Ministry ...